Circulating microRNAs and therapy-associated cardiac events in HER2-positive breast cancer patients: an exploratory analysis from NeoALTTO.

S PizzamiglioC M CiniselliE de AzambujaD Agbor-TarhA Moreno-AspitiaT M SuterA TramaM C De SantisL De CeccoM V IorioM SilvestriG PruneriPaolo VerderioS Di Cosimo

Published in: Breast cancer research and treatment (2024)

This study provides proof of concept that circulating microRNAs tested soon after treatment start could serve as biomarkers of cardiotoxicity in a very early stage in breast cancer patients receiving anti-HER2 therapy.

Keyphrases

early stage
positive breast cancer
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
peritoneal dialysis
prognostic factors
left ventricular
heart failure
stem cells
atrial fibrillation
mesenchymal stem cells
sentinel lymph node
young adults
neoadjuvant chemotherapy
data analysis